Skip to main content

Drug Interactions between Ahzantive and faricimab ophthalmic

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

aflibercept ophthalmic faricimab ophthalmic

Applies to: Ahzantive (aflibercept ophthalmic) and faricimab ophthalmic

GENERALLY AVOID: Coadministration of ophthalmic faricimab with other anti-vascular endothelial growth factor (VEGF) and/or other therapies (e.g., photodynamic therapy) for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema (DMO), and/or visual impairment due to macular edema secondary to retinal vein occlusion (RVO) in the same eye has not been evaluated.

MANAGEMENT: According to some authorities, concomitant use of ophthalmic faricimab with other anti-VEGF products, systemic or ocular, and/or other therapies (e.g., photodynamic therapies) in the same eye should generally be avoided. Clinical data characterizing the extent of this interaction are not available. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

References (3)
  1. (2024) "Product Information. Vabysmo (faricimab ophthalmic)." Roche Products Ltd
  2. (2024) "Product Information. Vabysmo (faricimab ophthalmic)." Genentech
  3. (2024) "Product Information. Vabysmo (faricimab ophthalmic)." Roche Products Pty Ltd

Drug and food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Ocular vegf antagonists

Therapeutic duplication

The recommended maximum number of medicines in the 'ocular VEGF antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ocular VEGF antagonists' category:

  • Ahzantive (aflibercept ophthalmic)
  • faricimab ophthalmic

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer